
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / alex / All</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal</description>
<pubDate>Sat, 03 Jan 2009 13:39:48 +0200</pubDate>
<language>en</language>
<item>
<title><![CDATA[Fighting Dengue Fever by Making Mosquitoes Die Young]]></title>
<link>http://www.worldpharmanews.net/Blogs/Fighting_Dengue_Fever_by_Making_Mosquitoes_Die_Young/</link>
<comments>http://www.worldpharmanews.net/Blogs/Fighting_Dengue_Fever_by_Making_Mosquitoes_Die_Young/</comments>
<pubDate>Sat, 03 Jan 2009 13:39:48 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Fighting_Dengue_Fever_by_Making_Mosquitoes_Die_Young/</guid>
<description><![CDATA[The simple model of mosquito-borne illness: A mosquito eats a blood meal from an infected person, then passes on the disease when it bites someone else. But the simple model omits a key piece in some disease stories. The bug causing the illness has to incubate inside the mosquito for a while &amp;#8212; about two weeks in the case of dengue &amp;#8212; before the mosquito infect other people. Some researchers want to take advantage of that wrinkle by shortening the (already pretty short) lifespan of wild mosquitoes, which could reduce the percentage of their lives when they&amp;#8217;re liable to spread disease.In a study published this week in the journal Science, a group of Australian researchers took Wolbachia, a type of bacteria that naturally infects many insects, and cultivated it to infect the kind of mosquitoes that spread dengue. They found that the bug significantly shortened mosquitoes&amp;#8217; lifespan, from somewhere around two months to somewhere around a month, give or take.    <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Emergency Room Workers Say Problems Are Rampant]]></title>
<link>http://www.worldpharmanews.net/Blogs/Emergency_Room_Workers_Say_Problems_Are_Rampant/</link>
<comments>http://www.worldpharmanews.net/Blogs/Emergency_Room_Workers_Say_Problems_Are_Rampant/</comments>
<pubDate>Sun, 07 Dec 2008 12:41:54 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Emergency_Room_Workers_Say_Problems_Are_Rampant/</guid>
<description><![CDATA[As if we needed more bad news about the dismal state of the nation&amp;#8217;s ERs, doctors and nurses who work in them don&amp;#8217;t have much confidence in their safety and worry about working conditions. Those are some of the findings from a study funded by the federal Agency for Healthcare Research and Quality and just published online by the Annals of Emergency Medicine. Lead author David Magid, an ER doc and senior scientist at the Kaiser Permanente Colorado Institute for Health Research, tells the Health Blog that the most surprising finding was how widespread the problems are&amp;#8211;striking every type of hospital. &amp;#8220;We found the same problems and issues in every region, in small and large ERs and in big academic medical centers and community hospitals,&amp;#8221; Magid says. &amp;#8220;I wasnt too surprised that patients are being cared for in the hallways, but I was surprised that one-third said it happened consistently.&amp;#8221;    <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[UnitedHealth Takes On Microsoft, Google With Online Health Venture]]></title>
<link>http://www.worldpharmanews.net/Blogs/UnitedHealth_Takes_On_Microsoft_Google_With_Online_Health_Venture/</link>
<comments>http://www.worldpharmanews.net/Blogs/UnitedHealth_Takes_On_Microsoft_Google_With_Online_Health_Venture/</comments>
<pubDate>Tue, 02 Dec 2008 00:09:37 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/UnitedHealth_Takes_On_Microsoft_Google_With_Online_Health_Venture/</guid>
<description><![CDATA[Not wishing to be outdone by the likes of Microsoft and Google, UnitedHealth Group today launched its own Web site for people to store their personal health information. The service, at  myoptumhealth.com  lets people create their own digital-health records, putting the health insurer into direct competition with Microsofts HealthVault  and Google Health. The WSJ  has the details.Microsoft launched its site just over a year ago, ahead of Google, which went live with its offering in February. All three sites provide their service free of charge. Like other health-portals, such as WebMD, UnitedHealths new site is open to all comers - not just clients of the insurer - and features information about medical conditions and diseases. The insurer also plans to market its products, such as medical, dental and vision insurance through the site.Rivals insurers, such as Aetna and WellPoint already offer digital-health records through their sites, but to a narrower group of consumers: health-plan members and employees of large corporate clients, WSJ writes.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Leftover Turkey Recipes: A Pressing Health Issue]]></title>
<link>http://www.worldpharmanews.net/Blogs/Leftover_Turkey_Recipes_A_Pressing_Health_Issue/</link>
<comments>http://www.worldpharmanews.net/Blogs/Leftover_Turkey_Recipes_A_Pressing_Health_Issue/</comments>
<pubDate>Sun, 30 Nov 2008 13:56:08 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Leftover_Turkey_Recipes_A_Pressing_Health_Issue/</guid>
<description><![CDATA[Before the Health Blog signs off for the day, we thought we'd consult with the American health establishment on a pressing question: What to do with leftover turkey. The establishment didn't disappoint.The National Heart, Lung and Blood Institute (part of NIH) has this basic turkey soup recipe. One public health tip that may already be familiar to many cooks: For a dish that's lower in saturated fat, let the soup cool and skim off the fat that condenses on the surface.For something a little heartier (no pun intended), consider the American Heart Association's Turkey Tetrazzini. The turkey is skinless, of course, and the evaporated milk is skim. The AHA calls it a &quot;great way to use turkey leftovers.&quot;Finally, diabetics might consider this turkey stew recipe, courtesy of NIH's National Diabetes Education Program. The recipe doesn't mention leftovers, but to our amateur eye, it looks like you could just skip the part about cooking the chunks of turkey in a skillet and start with the part where you put the turkey and the tomatoes in the casserole.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Wyeth Names Kamarck to Run Factories]]></title>
<link>http://www.worldpharmanews.net/Blogs/Wyeth_Names_Kamarck_to_Run_Factories/</link>
<comments>http://www.worldpharmanews.net/Blogs/Wyeth_Names_Kamarck_to_Run_Factories/</comments>
<pubDate>Sun, 23 Nov 2008 01:14:58 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Wyeth_Names_Kamarck_to_Run_Factories/</guid>
<description><![CDATA[When Wyeth named Michael Kamarck as its new head of manufacturing this week, we asked, &amp;#8220;Who is that guy?&amp;#8221;Wyeth indulged us. And we found out Kamarck, 57, was trained as a biochemist, and that he&amp;#8217;s been looking after biotech manufacturing for the company since joining in 2001 from Bayer.His goals in the new job, he told us in a telephone chat, are to increase efficiency across the board for the maker of small-molecule drugs, vaccines and biologics. &amp;#8220;What&amp;#8217;s most important to us right now is shortening the time to development and getting these products into the clinic and the market more quickly,&amp;#8221; he said.  Wyeth has had its share of manufacturing problems in the past. Besides a run of FDA trouble, Wyeth failed to meet demand at times for its widely used pneumococcal vaccine Prevnar and the anti-inflammatory biologic Enbrel, co-marketed with Amgen.Kamarck acknowledged that the demand for these products wasn&amp;#8217;t &amp;#8220;adequately anticipated&amp;#8221; early on. But Wyeth has beefed up infrastructure and improved manufacturing processes. The company opened a state-of-the-art factory in Ireland last year and has even patented some innovations to its manufacturing chain. And the company has been making a stockpile of a new, more complex version of Prevnar in anticipation of FDA approval in 2010.    <br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Stephen Colbert for FDA Commissioner?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Stephen_Colbert_for_FDA_Commissioner/</link>
<comments>http://www.worldpharmanews.net/Blogs/Stephen_Colbert_for_FDA_Commissioner/</comments>
<pubDate>Mon, 17 Nov 2008 10:08:32 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Stephen_Colbert_for_FDA_Commissioner/</guid>
<description><![CDATA[We are soooo late to this party, but it's such a delicious one that we just can't resist a weekend post. On Wednesday, Comedy Central's Stephen Colbert, of all people, weighed in with some remarkably trenchant analysis on the results of the Jupiter trial. That's the study that showed people with normal cholesterol but high C-reactive protein, a marker of inflammation, had a reduced risk of heart attack if they took AstraZeneca's statin Crestor.&quot;This is a great breakthrough in the battle to find things to prescribe to people who dont need them,&quot; he declared midway through a segment called &quot;Cheating Death with Dr. Stephen T. Colbert, D.F.A.&quot; (That's Doctor of Fine Arts, and is apparently qualification enough for some biting medical analysis.)&quot;True, the drug costs $100 a month,&quot; he explained. &quot;But that is a small price to pay to not have the heart attack that there's no way of knowing that you would have had.&quot;After a video clip of Stanford cardiologist Mark Hlatky sounding a cautionary note on the results, Colbert quipped, &quot;sounds like someone hasn't gotten enough free Crestor pens.&quot;The piece led Scientific American to suggest, in fun, that Colbert's name be added to the list of candidates for FDA Commissioner in the new administration. Another idea from SciAm: Launch The Colbert Journal of Medicine. Hear, hear! Only problem there would be finding true peers of Colbert to review the material. Thanks to SciAm for the great take (and headline).<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Rep. Dingell: Economic Stimulus Should Include NIH, Medicaid]]></title>
<link>http://www.worldpharmanews.net/Blogs/Rep-_Dingell_Economic_Stimulus_Should_Include_NIH_Medicaid/</link>
<comments>http://www.worldpharmanews.net/Blogs/Rep-_Dingell_Economic_Stimulus_Should_Include_NIH_Medicaid/</comments>
<pubDate>Fri, 14 Nov 2008 13:00:58 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Rep-_Dingell_Economic_Stimulus_Should_Include_NIH_Medicaid/</guid>
<description><![CDATA[Congress is about to meet in a lame duck session to try and help the economy by spending some extra money. John Dingell, the Dem who chairs the powerful House Energy and Commerce Committee, held a hearing today to share his ideas. Namely: Shell out some extra cash for Medicaid and NIH. Here&amp;#8217;s his statement.There are some pretty straightforward arguments for spending more money on Medicaid, which provides subsidized health insurance for the poor. States, which fund part of the program, are seeing their tax revenues plummet, even as workers are losing their jobs, and the employer-sponsored insurance that goes with them.Dingell also pointed out that NIH funding has been flat for the past several years, and argued that bonus funding for the agency would do more than pay for more research. &amp;#8220;The Federal dollars that NIH sends out into communities provide direct economic benefits at the local level, including increased employment and growth opportunities for universities, medical centers, and local companies,&amp;#8221; he said in the statement.House Speaker Nancy Pelosi has backed including Medicaid in the stimulus package, but there&amp;#8217;s been little talk of adding NIH to the list, Dow Jones Newswires reports.Meanwhile, Republican Sen. Chuck Grassley used Dingell&amp;#8217;s hearing as an occasion to return to a subject near and dear to his heart: Conflicts of interest and NIH money. &amp;#8220;Any effort to increase NIH funding should also include accurate, complete and transparent reporting of financial relationships between research doctors and the drug industry,&amp;#8221; Grassley said in a statement.&amp;#8221;    <br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Mercka4s Heart Remains Steadfast in Hunt for Cardiovascular Drugs]]></title>
<link>http://www.worldpharmanews.net/Blogs/Merckrsquos_Heart_Remains_Steadfast_in_Hunt_for_Cardiovascular_Drugs/</link>
<comments>http://www.worldpharmanews.net/Blogs/Merckrsquos_Heart_Remains_Steadfast_in_Hunt_for_Cardiovascular_Drugs/</comments>
<pubDate>Sun, 09 Nov 2008 21:54:02 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Merckrsquos_Heart_Remains_Steadfast_in_Hunt_for_Cardiovascular_Drugs/</guid>
<description><![CDATA[Merck wants the world to know that when it comes to developing new drugs for cardiovascular disease, the company is in the fight for the long haul.At the American Heart Association&amp;#8217;s annual scientific meeting underway now through Wednesday in New Orleans, the company is taking out &amp;#8220;Heart of Merck&amp;#8221; ads in the convention newspaper, showing a video on the topic at its booth in the exhibit hall, and talking to reporters about its commitment to what has been one of the most beneficial and lucrative franchises in the history of the drug industry. &amp;#8220;We have a legacy, we have this core competency,&amp;#8221; Dick Pasternak, Merck&amp;#8217;s vice president for cardiovascular clinical research, told the Health Blog over a cup of coffee in the Crescent City. &amp;#8220;We have a responsibility to the public to continue to fight the war against the biggest cause of death and disability.&amp;#8221;    <br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Wages Are a4Too Small a Donkeya4 to Carry the Load of Health Costs]]></title>
<link>http://www.worldpharmanews.net/Blogs/Wages_Are_lsquoToo_Small_a_Donkeyrsquo_to_Carry_the_Load_of_Health_Costs/</link>
<comments>http://www.worldpharmanews.net/Blogs/Wages_Are_lsquoToo_Small_a_Donkeyrsquo_to_Carry_the_Load_of_Health_Costs/</comments>
<pubDate>Sat, 08 Nov 2008 21:21:54 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Wages_Are_lsquoToo_Small_a_Donkeyrsquo_to_Carry_the_Load_of_Health_Costs/</guid>
<description><![CDATA[You think the cost of health care is hard on lower-middle-income families right now? In a few years, if current trends continue, it will be much worse.Families with a &amp;#8220;gross wage base&amp;#8221; between $20,000 and $60,000 a year are about to be swamped by health care costs, Princeton health economist Uwe Reinhardt argues in a guest post on the New York Times blog Economix.Gross wage base is basically all of the payroll expenses an employer pays for a person &amp;#8212; including salary as well as both the employer and employee&amp;#8217;s contributions to health insurance premiums.A family making $60,000 a year today is likely to be making about $80,000 in 2017, Reinhardt says, assuming 3% annual wage increases. And, based on current trends, health costs for a typical non-elderly family will top $33,000 that year, up from $15,600 in 2008. Before accounting for taxes, health care would account for some 40% of the family&amp;#8217;s budget. Reinhardt writes:These numbers, which are realistic, suggest that before long the gross wage base earned by American households will become too small a donkey to carry the load of the familys spending on health care. It will put before Americans an uncomfortable choice.Either Americans in the higher income strata must step up to the cashiers window to help subsidize, with higher income taxes, the health care of the most hard-working members of the lower income classes, or the United States will have to evolve toward a noticeable two-tiered or multi-tiered health care system, with bare-bones, low-tech health care for families in the bottom half of the income distribution and increasingly superior, high-tech health care for families in the upper-income strata.Health Blog Question for the Weekend: If you&amp;#8217;re in a high income bracket, would you pay higher taxes to subsidize health care for lower-middle-income families?Donkey by Hamed Saber via Flickr    <br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Why Big Pharma come to China]]></title>
<link>http://www.worldpharmanews.net/Corporate/Why_Big_Pharma_come_to_China/</link>
<comments>http://www.worldpharmanews.net/Corporate/Why_Big_Pharma_come_to_China/</comments>
<pubDate>Wed, 12 Mar 2008 00:44:52 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Why_Big_Pharma_come_to_China/</guid>
<description><![CDATA[Today, we take a look at large, multi-national pharmaceutical companies. Annie Fu finds out why they have come to China, and what that means for the industry. China is on the minds and lips of the CEO's of the large multi-national pharmaceutical companies, commonly referred to as Big Pharma. They are enthusiastic about China, for good reason.<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Study: Post-menopause hormone pills linked to cancer - USATODAY.com]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Study_Post-menopause_hormone_pills_linked_to_cancer_-_USATODAY-com/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Study_Post-menopause_hormone_pills_linked_to_cancer_-_USATODAY-com/</comments>
<pubDate>Wed, 05 Mar 2008 16:11:19 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Study_Post-menopause_hormone_pills_linked_to_cancer_-_USATODAY-com/</guid>
<description><![CDATA[Patients in the study, the Women's Health Initiative, took the hormone combination, sold under the brand name of Prempro, for an average of 5 years. Two or three years later, their risks of heart attacks, blood clots and strokes had returned to normal, according to the paper, published in today's) Journal of the American Medical Association. The pills' benefits - a decrease in the risk of fractures and colorectal cancer - also vanished.Yet &quot;the overall picture is clearly one of harm,&quot; says Marcia Stefanick, chair of the initiative's steering committee and a Stanford University School of Medicine professor. For the first time, Stefanick notes, the study findings suggest - although they don't prove - that hormone therapy also increases the risk of death, mainly because of an increase in cancer.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Analyzing the side effects of drug ads - USATODAY.com]]></title>
<link>http://www.worldpharmanews.net/Blogs/Analyzing_the_side_effects_of_drug_ads_-_USATODAY-com/</link>
<comments>http://www.worldpharmanews.net/Blogs/Analyzing_the_side_effects_of_drug_ads_-_USATODAY-com/</comments>
<pubDate>Wed, 05 Mar 2008 11:48:23 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Analyzing_the_side_effects_of_drug_ads_-_USATODAY-com/</guid>
<description><![CDATA[A few times every week, patients ask Jim King about drugs they've seen advertised. &quot;They'll say, 'I saw this ad on TV, and I think I have this medical problem,'&quot; says King, a family physician in Selmer, Tenn., who says he's not bothered by the requests. &quot;It gives me an opportunity to talk with the patient. It's amazing how many don't have the problem&quot; or need the drug they saw advertised.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The best pharma blogs, according to Pharmafocus  Corroxannaa4s Weblog]]></title>
<link>http://www.worldpharmanews.net/Blogs/The_best_pharma_blogs_according_to_Pharmafocus_«_Corroxannarsquos_Weblog/</link>
<comments>http://www.worldpharmanews.net/Blogs/The_best_pharma_blogs_according_to_Pharmafocus_«_Corroxannarsquos_Weblog/</comments>
<pubDate>Sun, 02 Mar 2008 23:32:18 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/The_best_pharma_blogs_according_to_Pharmafocus_«_Corroxannarsquos_Weblog/</guid>
<description><![CDATA[The internet loves a good scandal. From compromising celebrity videos to the latest political whisperings, whatever your interest in life, the chances are its seamier side will be covered somewhere on the web.This is just as true for pharma, where industry gossip, rumour and horror stories send many people online and these days their first stop is usually a weblog or blog. Once little more than online diaries, blogs have come to represent a key development in the next generation of internet applications known as Web 2.0.<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The New England Journal of Medicine - Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death ()]]></title>
<link>http://www.worldpharmanews.net/Product/The_New_England_Journal_of_Medicine_-_Aprotinin_during_Coronary-Artery_Bypass_Grafting_and_Risk_of_Death_/</link>
<comments>http://www.worldpharmanews.net/Product/The_New_England_Journal_of_Medicine_-_Aprotinin_during_Coronary-Artery_Bypass_Grafting_and_Risk_of_Death_/</comments>
<pubDate>Sun, 24 Feb 2008 00:21:39 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/The_New_England_Journal_of_Medicine_-_Aprotinin_during_Coronary-Artery_Bypass_Grafting_and_Risk_of_Death_/</guid>
<description><![CDATA[Conclusions: Patients who received aprotinin alone on the day of CABG surgery had a higher mortality than patients who received aminocaproic acid alone. Characteristics of neither the patients nor the surgeons explain the difference, which persisted through several approaches to control confounding.<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Scientific Misconduct Blog: What is the half-life of a pharmaceutical scientific scandal?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_What_is_the_half-life_of_a_pharmaceutical_scientific_scandal/</link>
<comments>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_What_is_the_half-life_of_a_pharmaceutical_scientific_scandal/</comments>
<pubDate>Sat, 16 Feb 2008 22:17:22 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_What_is_the_half-life_of_a_pharmaceutical_scientific_scandal/</guid>
<description><![CDATA[Using Google Trends it is possible to plot the frequency of google searches against time, as well as the incidence of news reports for particular key words (with flags showing the timing of key incidents). I thought it would be interesting to look at a few scientific scandals<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Merck Resolves Federal and State Investigations]]></title>
<link>http://www.worldpharmanews.net/Corporate/Merck_Resolves_Federal_and_State_Investigations/</link>
<comments>http://www.worldpharmanews.net/Corporate/Merck_Resolves_Federal_and_State_Investigations/</comments>
<pubDate>Sat, 09 Feb 2008 00:33:32 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Merck_Resolves_Federal_and_State_Investigations/</guid>
<description><![CDATA[Merck &amp; Co., Inc. said that it has reached civil settlements with federal and state authorities to resolve longstanding investigations related to disputes over the proper calculation of Medicaid rebates as well as certain past sales and marketing activities that ended in 2001.The settlements do not constitute an admission by Merck of any liability or wrongdoing.  Merck believes its pricing and sales and marketing policies and practices were consistent with all applicable regulations and contracts during the relevant time.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  Glaxo Wins Paxil Suicide Case Due To Preemption]]></title>
<link>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Glaxo_Wins_Paxil_Suicide_Case_Due_To_Preemption/</link>
<comments>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Glaxo_Wins_Paxil_Suicide_Case_Due_To_Preemption/</comments>
<pubDate>Sun, 03 Feb 2008 21:03:13 +0200</pubDate>
<dc:creator>alex</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Glaxo_Wins_Paxil_Suicide_Case_Due_To_Preemption/</guid>
<description><![CDATA[A federal judge in California dismissed a case brought by the family of a 13-year-old girl who committed suicide while taking the antidepressant, citing a controversial rule that FDA approval of a drug preempts state lawsuits challenging safety, efficacy, or labeling. At issue is whether patients can sue a drugmaker through state law when a product has already been approved by the FDA, a notion the US Supreme Court is expected to decide after agreeing to review a different case.In the Paxil case, US District Court Judge Frank Damrell, Jr. dismissed the suit &quot;on the grounds that, under state law, all of the claims required showing that Glaxo should have included a warning in Paxil's labeling in 1997 that there was an increased risk of suicidality.&quot; And so he decided the lawsuit created &quot;a direct conflict with the federal labeling requirements for Paxil established&quot; by the FDA, &quot;preempting the plaintif's claims, according to a statement issued by Glaxo's attorneys.<br/><br/>2 Vote(s) ]]></description>
</item>

</channel>
</rss>
